The move to Schedule III marks the greatest change to U.S. drug laws since 1970 and represents a new future for the $32 billion cannabis industry.

Reclassification to a Schedule III drug and possible Medicare coverage for pot could unlock new investment from pharmaceutical companies.

The move to Schedule III marks the greatest change to U.S. drug laws since 1970 and represents a new future for the $32 billion cannabis industry.